Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of DCVAC/PCa in metastatic castration-resistant prostate cancer
2011-004735-32Phase 2Completed
- Sponsor
- SOTIO Biotech
- Start
- Oct 2011
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in metastatic castration-resistant prostate cancer (mCRPC) comparing DCVAC/PCa with Control / standard of care (2 arms). Primary endpoint: Overall survival at 34 months. Started Oct 2011; status: completed.
02
Drugs
DCvac
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2011-004735-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004735-32.